Northeastern's CenSSIS announces research agreement with ART Advanced Research Technologies

June 12, 2002

Northeastern University's Center for Subsurface Sensing and Imaging Systems (CenSSIS), a National Science Foundation (NSF) Engineering Research Center, and ART Advanced Research Technologies Inc. (ART) (TSE "ARA"), a leading developer of optical and infrared imaging technologies for the detection of anomalies in the medical sector and the electronics industry, are pleased to announce that ART has recently become a business partner and member of CenSSIS.

As a CenSSIS partner, ART will have complete access to, and the ability to leverage, all core research results from CenSSIS thus accelerating ART's development process. ART will play a key role in supporting the basic research and in guiding CenSSIS researchers toward improved medical imaging technologies. Furthermore, as a member of the CenSSIS Industrial Advisory Board, ART will counsel CenSSIS on the strategic direction of its research and educational programs. ART is the first international business to join the network of CenSSIS business partners, which include Raytheon, Mercury Computer Systems, The MathWorks and Lockheed Martin.

"ART's optical imaging technology will be the cornerstone in the validation of the sophisticated physics-based information extraction techniques which are at the heart of the advances being made at CenSSIS", commented Dr. Eric Miller, Associate Professor of electrical and computer engineering at Northeastern University. "Close collaboration between researchers at ART and CenSSIS will provide the type of mutual feedback required to advance the state of the art in the area of tomographic imaging while yielding tangible results that have the potential for having a positive impact on a crucial societal problem: the fight against breast cancer", added Dr. Miller.

"ART is very pleased to be collaborating with CenSSIS", stated Richard Boudreault, Vice President, Research and Development of ART. "As a CenSSIS partner, ART will have access to core intellectual property and will benefit from a most stimulating and dynamic scientific network", added Mr. Boudreault. "This will allow us to improve on biomedical image delivery through innovative algorithms".
-end-
About CenSSIS

Headquartered in Boston at Northeastern University, CenSSIS is a National Science Foundation Cross-disciplinary Engineering Research Center. It seeks to revolutionize the ability to detect and image objects or conditions that are underground, underwater, embedded within cells or inside the human body. The CenSSIS multi-disciplinary approach combines expertise in wave physics, sensor engineering, image processing and inverse scattering with rigorous performance testing to create new sensing system prototypes.

CenSISS has core academic partnerships with Boston University (BU), Rensselaer Polytechnic Institute (RPI) and University of Puerto Rico at Mayagüez (UPRM). The Center's core strategic affiliates include Lawrence Livermore National Laboratory (LLNL), Massachusetts General Hospital (MGH), Brigham and Women's Hospital (BWH) and Woods Hole Oceanographic Institution (WHOI). For more information about CenSSIS, go to www.censsis.neu.edu.

About ART

ART Advanced Research Technologies Inc. is a North American company that is involved in the research, design, development, and marketing of optical and infrared imaging technologies used in the detection of anomalies in the medical sector and the electronics industry. ART is in the process of bringing to market an optical imaging device to detect and diagnose breast anomalies. The device, known as SoftScan®, represents an innovative imaging solution for the detection of breast lesions without the adverse consequences associated with traditional technology. SoftScan® uses the time domain technique in optical imaging, which generates the most information possible about tissue. ART is also working on the development of a novel and proprietary molecular imaging technology, designed to characterize and measure cellular and molecular processes and pathways. With respect to the electronics industry, ART is currently commercializing its ISIS® products, which are based on infrared verification imaging technology, and are used to detect defects in printed circuit board assemblies. ART has been listed on the Toronto Stock Exchange since June 29, 2000 (TSE: "ARA"). For more information about ART go to www.art.ca.

About SoftScan®

ART's SoftScan® optical breast imaging device produces a functional image that can depict blood volumes and blood oxygen content simultaneously. With this combination of images, the SoftScan® device may permit the detection of anomalies in the breast that previously went undetected and may, in turn, be better able to determine whether a tumor is malignant or benign.

Northeastern University

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.